Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 4/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL55991 | 0.89 | HPGD (0.47) | NR1H2USP2SMN1; SMN2HPGDSTS | |
| SCHEMBL29718457 | 0.89 | HPGD (0.47) | NR1H2USP2SMN1; SMN2HPGDSTS | |
| SCHEMBL22531390 | 0.86 | MEN1 (0.50) | USP2SMN1; SMN2HPGDSTSEPHX1 | |
| SCHEMBL4183086 | 0.85 | NR1H2 (0.50) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL56603 | 0.84 | HPGD (0.53) | USP2SMN1; SMN2HPGDSTSRECQL | |
| Hydrochloric Acid SCHEMBL28063086 | 0.84 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL20599655 | 0.84 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL24695326 | 0.82 | NR1H2 (0.55) | NR1H2USP2SMN1; SMN2HPGDSTS | |
| SCHEMBL21640381 | 0.82 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2HPGDSTS | |
| SCHEMBL24695327 | 0.82 | NR1H2 (0.55) | NR1H2USP2SMN1; SMN2HPGDSTS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105622469-A | Preparation method of alkyl sulfonyl chloride containing nitrogen and fluorine | HANDE SCIENCES CO LTD | 2016-06-01 | — | — | CN | claimed |
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260109711-A1 | MACROCYCLIC SULFONAMIDE MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) | 2026-04-02 | — | — | US | disclosed |
| US-20260008778-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250304575-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | GALAPAGOS NV (BE) | 2025-10-02 | — | — | US | disclosed |
| EP-4616913-A2 | GCN2 INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2025-09-17 | — | — | EP | disclosed |
| EP-3746075-B1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2025-09-03 | — | — | EP | disclosed |
| EP-4574830-A1 | ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Guangzhou Vinnocent Pharmaceutical Limited (CN) | 2025-06-25 | — | — | EP | disclosed |
| WO-2025103502-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20150225408-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | PFIZER INC. | 2015-08-13 | — | — | US | disclosed |
| WO-2015113920-A1 | AMINO-SUBSTITUTED ISOTHIAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-06 | — | — | WO | disclosed |
| US-9035074-B2 | Pyrrolo[2,3-D]pyrimidine derivatives | PFIZER INC. (US) | 2015-05-19 | — | — | US | disclosed |
| WO-2014139328-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140243312-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2014128591-A1 | PYRROLO [2, 3 -D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF JANUS- RELATED KINASES (JAK) | PFIZER INC. (US) | 2014-08-28 | — | — | WO | disclosed |
| US-20130216497-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES | 2013-08-22 | — | — | US | disclosed |
| US-8426411-B2 | Tricyclic compounds | ABBOTT LABORATORIES (US) | 2013-04-23 | — | — | US | disclosed |
| WO-2012020215-A1 | AMINO- IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN OR LIPID KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-02-16 | — | — | WO | disclosed |
| US-20110311474-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | KIF2C, KIF5B, KIF5C | NR1H2 745/4885USP2 2094/4885SMN1; SMN2 218/4885 |
| US-20260109711-A1 | MACROCYCLIC SULFONAMIDE MODULATORS | HCRTR2, HCRTR1, CNR1 | NR1H2 48/4885USP2 3574/4885SMN1; SMN2 1021/4885 |
| US-20150225408-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | JAK3, JAK1, JAK2 | NR1H2 4785/4885USP2 2500/4885SMN1; SMN2 4382/4885 |
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | STS, NR5A1, CYP21A2 | NR1H2 152/4885USP2 1571/4885SMN1; SMN2 3395/4885 |
| US-20250304575-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | SNCA, PSEN2, PSEN1 | NR1H2 451/4885USP2 3352/4885SMN1; SMN2 22/4885 |
| US-20260008778-A1 | COMPOUNDS AND USES THEREOF | BRD9, BCL9L, BCL9 | NR1H2 1565/4885USP2 2537/4885SMN1; SMN2 26/4885 |
| US-20110311474-A1 | Novel Tricyclic Compounds | CYP11B2, CYP11B1, ABCB1 | NR1H2 297/4885USP2 4791/4885SMN1; SMN2 2947/4885 |
| US-20130216497-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | NR1H2 297/4885USP2 4791/4885SMN1; SMN2 2947/4885 |
| US-20140243312-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | JAK3, JAK1, JAK2 | NR1H2 4785/4885USP2 2500/4885SMN1; SMN2 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.